PT  - JOURNAL ARTICLE
AU  - YASUHIRO HASHIMOTO
AU  - YOICHIRO YOSHIDA
AU  - TEPPEI YAMADA
AU  - NAOYA AISU
AU  - GUMPEI YOSHIMATSU
AU  - FUMIHIRO YOSHIMURA
AU  - SUGURU HASEGAWA
TI  - Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs
AID  - 10.21873/anticanres.14464
DP  - 2020 Aug 01
TA  - Anticancer Research
PG  - 4655--4661
VI  - 40
IP  - 8
4099  - http://ar.iiarjournals.org/content/40/8/4655.short
4100  - http://ar.iiarjournals.org/content/40/8/4655.full
SO  - Anticancer Res2020 Aug 01; 40
AB  - In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU were developed to reduce toxicity, extend the duration of action, and increase tumour selectivity of 5-FU. These drugs are important in daily practice because of their ease of administration. Dose adjustment of 5-FU prodrugs by TDM is expected to reduce its toxicity and improve its efficacy. This review focuses on data from a recent study of personalized treatment using TDM of 5-FU and its prodrugs.